J
Jung-Ki Yoon
Researcher at Harvard University
Publications - 10
Citations - 689
Jung-Ki Yoon is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications receiving 582 citations.
Papers
More filters
Journal ArticleDOI
Genome-Wide Identification of Human RNA Editing Sites by Parallel DNA Capturing and Sequencing
Jin Billy Li,Erez Y. Levanon,Jung-Ki Yoon,John Aach,Bin Xie,Emily M LeProust,Kun Zhang,Yuan Gao,George M. Church +8 more
TL;DR: An unbiased genome-wide approach was used to identify 239 sites (in 207 target genes), with stringent criteria for editing, which included 10 of the 13 known edited genes and suggested that many more human genes may be edited at lower frequencies.
Journal ArticleDOI
Multiplex padlock targeted sequencing reveals human hypermutable CpG variations
Jin Billy Li,Yuan Gao,John Aach,Kun Zhang,Gregory V. Kryukov,Bin Xie,Annika Ahlford,Jung-Ki Yoon,Abraham M. Rosenbaum,Alexander Wait Zaranek,Emily M LeProust,Shamil R. Sunyaev,George M. Church +12 more
TL;DR: The 10,000-fold improvement of a previously developed padlock-based approach to identifying genetic variations in hypermutable CpG regions across human chromosome 21 is reported, and it is suggested that targeted C pG resequencing is an efficient way to identify common and rare genetic variations.
Journal ArticleDOI
Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis.
Serine Avagyan,Jonathan E. Henninger,W. P. Mannherz,Meeta Mistry,Jung-Ki Yoon,Song P. Yang,Margaret C. Weber,Jessica L Moore,Leonard I. Zon,Leonard I. Zon +9 more
TL;DR: In this paper, a technique that combines mosaic mosaics was developed to expand a mutant hematopoietic stem and progenitor cell (HSPC) into a HSPC.
Journal ArticleDOI
Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
TL;DR: In this article , the authors investigated the best prognostic biomarker for patients with acute exacerbation (AE) and interstitial lung disease (ILD) and found that Krebs von den Lungen-6 (KL-6) was an independent predictor of in-hospital mortality.